Skip to main content

Table 2 Frequency of NPAEs with high-dose tafenoquine/chloroquine in vivax malaria patients [81]

From: Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

Adverse event, n (%)Tafenoquine
300 mg q.d. × 7 days (N = 18)
Tafenoquine
600 mg q.d. × 3 days (N = 19)
Tafenoquine
600 mg single dose (N = 18)
Primaquine
15 mg q.d. × 14 days (N = 12)
Any NPAE8 (44)8 (42)4 (22)6 (50)
Vertigo8 (44)8 (42)4 (22)3 (25)
Headache4 (22)4 (21)2 (11)4 (33)